Genetesis is a medtech firm that has developed the CardioFlux FAC, an FDA cleared biomagnetic imaging device poised to streamline chest pain triage workflows in the ER. CardioFlux leverages magnetocardiography, which has been studied for over 40 years, to rapidly and safely rule out coronary artery disease. The procedure is reimbursed by Medicare, and we are raising our Series B to help patients and providers gain access to our technology.